Skip to main content

Table 5 The PK profiles of navoximod

From: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Species CL (mL/min/kg) Cmax (ng/mL) t1/2 (h) F (%) AUC (ng h/mL)
Rat 44.6 1560 1.44 41.5 3930
Mice 27.5 2257 3.9 69.0 6132
Dog 53.7 1400 4.8 22.3 3127
  1. CL, Plasma clearance; Cmax, peak concentration; t1/2, half-life; F, Oral bioavailability; AUC, area under the concentration-time curve